<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/38CDB009-CBB8-4780-8D7D-DA9EA63203A4"><gtr:id>38CDB009-CBB8-4780-8D7D-DA9EA63203A4</gtr:id><gtr:name>Quadrant Visual Solutions</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/F1391626-62E0-4058-BB37-84B708F6AEFD"><gtr:id>F1391626-62E0-4058-BB37-84B708F6AEFD</gtr:id><gtr:name>Novolytics Ltd</gtr:name><gtr:address><gtr:line1>Suite 41, Barclays Venture Centre</gtr:line1><gtr:line2>Sir William Lyons Road</gtr:line2><gtr:postCode>CV4 7EZ</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Immunity and Infection</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/38CDB009-CBB8-4780-8D7D-DA9EA63203A4"><gtr:id>38CDB009-CBB8-4780-8D7D-DA9EA63203A4</gtr:id><gtr:name>Quadrant Visual Solutions</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F1391626-62E0-4058-BB37-84B708F6AEFD"><gtr:id>F1391626-62E0-4058-BB37-84B708F6AEFD</gtr:id><gtr:name>Novolytics Ltd</gtr:name><gtr:address><gtr:line1>Suite 41, Barclays Venture Centre</gtr:line1><gtr:line2>Sir William Lyons Road</gtr:line2><gtr:postCode>CV4 7EZ</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/51E82E1F-EBD9-47D7-9A9E-12F2A52B9D4F"><gtr:id>51E82E1F-EBD9-47D7-9A9E-12F2A52B9D4F</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Hawkey</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0701570"><gtr:id>0C50E05F-CF4E-4072-AA9A-8DE1A413EB3C</gtr:id><gtr:title>Diagnostic, treatment &amp;amp; behavioural interventions to reduce MRSA colonisati</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0701570</gtr:grantReference><gtr:abstractText>We will use our knowledge of the way in which MRSA colonises and spreads from patient to patient to design innovative methods of prevention and thereby reduce MRSA infection in hospitals</gtr:abstractText><gtr:technicalSummary>MRSA colonisation is one of the major challenges facing the NHS. Colonisation of patients by MRSA invariably precedes infection and transmission from both colonised and infected patients leads to outbreaks. We will identify the key organism and patient factors responsible for colonisation and apply innovative new methods to eliminating carriage and, by behavioural modification, transmission. The impact of these interventions will be carefully evaluated by expert economic and operational modellers.</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-13</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-01-14</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>48594</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Quadrant Visual Solutions</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Healthcare link analysis tool</gtr:description><gtr:id>D7DD072E-92FA-40FF-A5A4-28E4AB6A4E9B</gtr:id><gtr:impact>Our UKCRC outline application was short-listed and MIRACOL was invited to submit a full application. The collaboration with Quadrant Visual Solutions will result in the development of a link analysis tool capable of immediate translation in a number of healthcare settings.</gtr:impact><gtr:piContribution>A UKCRC Strategic Development Grant (SDG) enabled our newly formed consortium (MIRACOL group) to forge links with another SME - Quadrant Visual Solutions - to develop a proposal for a link analysis tool capable of immediate translation in a number of healthcare settings. This proposal was detailed in a UKCRC Translational Infection Research Initiative outline application. The application was short-listed and MIRACOL was invited to submit a full application.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novolytics Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRSA specific bacteriophage therapy</gtr:description><gtr:id>2CBB1F9A-9950-4C49-AA80-7C5A4B21CB0D</gtr:id><gtr:impact>Our UKCRC outline application was short-listed and MIRACOL was invited to submit a full application. The proposed research involving Novolytics will enhance the understanding of the effects of phage therapy compared to mupirocin in the decolonisation of S. aureus from patients in hospitals.</gtr:impact><gtr:piContribution>A UKCRC Strategic Development Grant (SDG) enabled our newly formed consortium (MIRACOL group) to strengthen links with Novolytics to develop future research which was included in a UKCRC Translational Infection Research Initiative outline application. The application was short-listed and MIRACOL was invited to submit a full application.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">G0701570</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>